A guide to drug discovery: Bayesian clinical trials

Nature Reviews Drug Discovery

Volumn 5, Issue 1, 2006, Pages 27-36

  Berry, Donald A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; IDARUBICIN; PLACEBO; PRAVASTATIN; PRAVIGARD PAC; TRASTUZUMAB; TROXACITABINE;

ACCURACY; ALGORITHM; BAYES THEOREM; BIOSTATISTICS; BREAST CANCER; CANCER REGRESSION; CEREBROVASCULAR ACCIDENT; CLINICAL RESEARCH; CLINICAL STUDY; CLINICAL TRIAL; DECISION MAKING; DOSE RESPONSE; DRUG EFFICACY; EXPERIMENTAL DESIGN; HUMAN; INTERMETHOD COMPARISON; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; METHODOLOGY; MYELOID LEUKEMIA; NEUROPROTECTION; NULL HYPOTHESIS; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROBABILITY; RANDOMIZATION; REVIEW; SAMPLE SIZE; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; SURVIVAL; TREATMENT OUTCOME; STATISTICAL ANALYSIS; STATISTICS;

BAYES THEOREM; CLINICAL TRIALS; DATA INTERPRETATION, STATISTICAL;

EID: 33644861229     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd1927     Document Type: Review

References (22)

1. Berry, D. A. Statistics: A Bayesian Perspective (Duxbury, California, 1996).
2. Christensen R. Testing Fisher, Neyman, Pearson, and Bayes. Am. Statistician 59, 121-126 (2005).
3. Berry, D. A. Interim analysis in clinical trials: The role of the likelihood principle. Am. Statistician 41, 117-122 (1987).
4. Berger, J. O. & Berry, D. A. Statistical analysis and the illusion of objectivity. Am. Scientist 76, 159-165 (1988).
5. Berger, J. O. & Wolpert, R. L. The Likelihood Principle (Institution of Mathematical Statistics, California, 1988).
6. Berry, D. A. & Stangl, D. K. Bayesian Biostatistics (Marcel Dekker, New York, 1996).
7. Buzdar, A. U. et al. Significantly higher pathological complete remission rate following neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin-containing chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J. Clin. Oncol. 23, 3676-3685 (2005).
8. Inoue, L. Y. T., Berry, D. A. & Parmigiani, G. Relationship between Bayesian and frequentist sample size determination. Am. Statistician 59, 79-87 (2005).
9. Cheng, Y., Su, F. & Berry, D. A. Choosing sample size for a clinical trial using decision analysis. Biometrika 90, 923-936 (2003).
10. Giles, F. J. et al. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J. Clin. Oncol. 21, 1722-1727 (2003).
11. Berry, D. A. et al. in Case Studies in Bayesian Statistics V (eds Gatsonis, C., Carlin, B. & Carriquiry, A.) 99-181 (Springer, New York, 2001).
12. Malakoff, D. Statistics: Bayes offers a 'new' way to make sense of numbers. Science 286, 1460-1464 (1999).
13. Farr-Jones, S. Better statistics. BioCentury 9, 1-6 (2001).
14. Krams, M. et al. Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN). An adaptive dose-response study of UK-279, 276 in acute ischemic stroke. Stroke 34, 2543-2548 (2003).
15. Berry, D. A. in Cancer Medicine 6th edn (eds Holland, J. et al.) 465-478 (Decker, London, 2003).
16. Berry, D. A. Bayesian statistics and the efficiency and ethics of clinical trials. Statistical Sci. 19, 175-187 (2004).
17. Spiegelhalter, D. J., Abrams, K. R. & Myles, J. P. Bayesian Approaches to Clinical Trials and Health-Care Evaluation (Wiley, Chichester, 2004).
18. Berry, S. M. & Berry, D. A. Accounting for multiplicities in assessing drug safety: A three-level hierarchical mixed model. Biometrics 60, 418-426 (2004).
19. Inoue, L. Y. T., Thall, P. & Berry, D. A. Seamlessly expanding a randomized phase II trial to phase III. Biometrics 58, 264-272 (2002).
20. Hennekens, C. H. et al. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: Randomized and observational comparisons of secondary prevention trials and their meta-analysis. Arch. Intern. Med. 164, 40-44 (2004).
21. Berry, S. M. et al. Bayesian survival analysis with nonproportional hazards: Metanalysis of pravastatin-aspirin. J. Am. Statistical Assoc. 99, 36-44 (2004).
22. Edwards, W., Lindman, H. & Savage, L. J. Bayesian statistical inference for psychological research. Psychol. Rev. 70, 193-242 (1963).